Click Here to return To Results

 

Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999 See this aricle in Pubmed Article Abstract To compare efficacy of interferon Beta-1a, 22 ug or 44 ug weekly, with placebo in relapsing MS. Uncertainty exists concerning the optimal dose regimen for interferon Beta in relapsing-remitting MS. Many patients and physicians prefer the convenience and lesser side effects of an injection given once weekly (qw) as opposed to three times weekly. Pharmacokinetic data and information on biologic markers suggest that this frequency may be suboptimal. These data confirm an MRI benefit of in terferon Beta-1a at low dose in MS, but highlight the limited clinical effect. Taken together with other studies, the data demonstrate a dose-effect relationship for both clinical and MRI variables.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction gadolinium interferon interferon beta 1-a MRI MRI,abnormal MRI,contrast enhanced MRI,serial multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of treatment of neurologic disorder

Click Here to return To Results